Abiomed losses narrow for FY2009, Q4; bolstered by strong Impella sales

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

Abiomed, a provider of heart support technologies, has reported fourth quarter of fiscal 2009 revenue of $19.6 million, which is up 12 percent compared to revenue of $17.5 million for the 2008 fourth fiscal quarter.

Total revenue for the 12 months ended March 31 was $73.2 million, up 24 percent compared to revenue of $58.9 million for the full year fiscal 2008. Full-year fiscal 2009 worldwide Impella revenue was $36.4 million, up 196 percent compared to Impella revenue of $12.3 million for fiscal 2008, due to its FDA approval.

The Danvers, Mass.-based company said its generally accepted accounting principles (GAAP) net loss was $8.5 million for this quarter, compared to a GAAP net loss of $15 million during the fourth quarter of fiscal 2008. The full year fiscal 2009 GAAP net loss was $31.6 million, compared to a GAAP net loss of $40.9 million for the full year fiscal 2008.

For its 2009 fiscal fourth quarter, the company said its worldwide Impella revenue was $11.2 million, up 124 percent compared to revenue of $5 million for the year-ago quarter.